
News|Videos|August 29, 2025
Lessons from Psoriasis Action Month: Insights from Three Patient Journeys
Author(s)Lana Pine
Multidisciplinary management and patient-centered care are critical for optimizing outcomes in complex or severe psoriasis cases.
Advertisement
Advertisement
As part of Psoriasis Action Month, patient narratives reveal the complex interplay between disease severity, comorbidities, and psychosocial burden in psoriasis management. Cases like those of Ayesha Patrick, Brian Lehrschall, and Janene Tirado illustrate the heterogeneity of psoriasis, spanning common chronic plaque forms, rare pustular variants, and the compounded impact of multimorbidity. These stories underscore the importance of timely diagnosis, culturally competent care, and multidisciplinary management in optimizing outcomes.
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.

Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.

Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.

Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.

Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
Advertisement
Advertisement

